David I Quinn, MD

Clinical Professor of Medicine

Image of David I Quinn, MD
Is this your profile? Click to edit

Overview

David Ian Quinn MBBS Honors Class I, PhD, FRACP FACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.

He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 200 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Prostate Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries.

Dr. Quinn’s current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.

Awards

  • University of New South Wales: Gordon Lowe Memorial Prize, 1987
  • University of New South Wales: Honours First Class Bachelor of Medicine, Bachelor of Surgery, 1987
  • National Health and Medical Research Council of Australia: Postgraduate Medical Scholarship, 1996
     – 1999
  • Postgraduate Medical Council of New South Wales: Distinguished Contribution Award, 2000
  • St. Vincent’s Clinic Foundation: The David Wilson Travelling Fellowship, 2000
  • National Health and Medical Research Council of Australia: Neil Hamilton Fairley Fellowship, 2000
     – 2003
  • Royal Australasian College of Physicians: Vincent Fairfax Family Fellowship, 2001
  • USC Norris Cancer Center and Hospital: The Spirit of Norris Award, 2002
  • Castle Connolly Medical: America’s Top Doctors, 2010

Research Funding

  • NCTN – Network Lead Academic Participating Site: USC
    NIH · UG1CA180830 · Apr 17, 2014 – Feb 29, 2032 · Role: Co-Principal Investigator
  • NCI NCTN- Network Lead Academic Participating Site: USC
    NIH · U10CA180830 · Apr 17, 2014 – Feb 28, 2019 · Role: Co-Principal Investigator

Publications

  • Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis. Blood Adv. 2026 May 26; 10(10):3543-3553.. View in PubMed
  • Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma. Curr Probl Cancer. 2026 Aug; 63:101294.. View in PubMed
  • The United Kingdom National Programme of DCD heart transplantation: Timings, techniques, feasibility, and outcomes with abdominal normothermic regional perfusion. J Heart Lung Transplant. 2026 May 04.. View in PubMed
  • Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial. Clin Cancer Res. 2026 Apr 06.. View in PubMed
  • The feasibility of implementing and evaluating individualised digital prehabilitation prior to major elective surgery in adults aged ≥ 50 years: the PreActiv intervention. Perioper Med (Lond). 2026 Mar 03; 15(1).. View in PubMed
  • Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2025 Nov 29; 95(1):115.. View in PubMed
  • Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas. Blood Neoplasia. 2026 Feb; 3(1):100176.. View in PubMed
  • Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies. Clin Lung Cancer. 2026 Mar; 27(2):214-226.e5.. View in PubMed
  • Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer. Cancers (Basel). 2025 May 21; 17(10).. View in PubMed
  • Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate Cancer. medRxiv. 2025 Apr 22.. View in PubMed